NCT05375734View on ClinicalTrials.gov

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pulmonary Pleomorphic CarcinomaImmunotherapyTislelizumab
Interventions
DRUG

Tislelizumab in combination with anlotinib

Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W

Trial Locations (1)

330006

RECRUITING

The Second Afiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Second Affiliated Hospital of Nanchang University

OTHER